Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Daniel

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Psychiatry|January 20, 2004
Tolerability of ziprasidone: an expanding perspectiveDavid G Daniel
Journal of Emergency Nursing|December 26, 2002
Recent developments in pharmacotherapy for the acutely psychotic patientDavid G Daniel
Innovations in Clinical Neuroscience|February 8, 2018
Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future DirectionsMark G A Opler, Christian Yavorsky, David G Daniel
Journal of Clinical Psychopharmacology|November 19, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidonePeter J Weiden, David G Daniel, George Simpson, et al.
International Clinical Psychopharmacology|April 23, 2004
The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapyDavid G Daniel, Dan L Zimbroff, Rachel H Swift, et al.
The Journal of Clinical Psychiatry|August 3, 2010
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophreniaJohn M Kane, Steven G Potkin, David G Daniel, et al.
Clinical Schizophrenia & Related Psychoses|June 23, 2011
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factorDavid G Daniel, Larry Alphs, Pilar Cazorla, et al.
Innovations in Clinical Neuroscience|January 27, 2015
Consensus recommendations on rater training and certification, Mark D West, David G Daniel, et al.
European Child & Adolescent Psychiatry|March 11, 2025
Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trialsJoan Busner, Eric A Youngstrom, Joshua A Langfus, et al.
Schizophrenia Bulletin|January 29, 2011
Methodological issues in negative symptom trialsStephen R Marder, David G Daniel, Larry Alphs, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Psychiatry|January 20, 2004
Tolerability of ziprasidone: an expanding perspectiveDavid G Daniel
Journal of Emergency Nursing|December 26, 2002
Recent developments in pharmacotherapy for the acutely psychotic patientDavid G Daniel
Innovations in Clinical Neuroscience|February 8, 2018
Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future DirectionsMark G A Opler, Christian Yavorsky, David G Daniel
Journal of Clinical Psychopharmacology|November 19, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidonePeter J Weiden, David G Daniel, George Simpson, et al.
International Clinical Psychopharmacology|April 23, 2004
The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapyDavid G Daniel, Dan L Zimbroff, Rachel H Swift, et al.
The Journal of Clinical Psychiatry|August 3, 2010
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophreniaJohn M Kane, Steven G Potkin, David G Daniel, et al.
Clinical Schizophrenia & Related Psychoses|June 23, 2011
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factorDavid G Daniel, Larry Alphs, Pilar Cazorla, et al.
Innovations in Clinical Neuroscience|January 27, 2015
Consensus recommendations on rater training and certification, Mark D West, David G Daniel, et al.
European Child & Adolescent Psychiatry|March 11, 2025
Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trialsJoan Busner, Eric A Youngstrom, Joshua A Langfus, et al.
Schizophrenia Bulletin|January 29, 2011
Methodological issues in negative symptom trialsStephen R Marder, David G Daniel, Larry Alphs, et al.
Pageof 4